Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 1;10(6):e004440. doi: 10.1136/jitc-2021-004440

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

The TCR fraction is associated with better outcome after ICI in PD-L1 positive NSCLC cases. (A) Overview of the TCR burden analysis protocol. (B) Forest plots showing the PFS and OS Hazard ratios of cases in the NSCLC cohort using a Cox univariate model. Cases were stratified by PD-L1 expression into positive (B) and negative (C) by immunohistochemistry. (D). Kaplan-Meier graphical analysis of PFS (D) and OS (E) of NSCLC cases stratified by the median TCR fraction and by PD-L1 status (F and G). ICI, Immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival; TCR, T cell receptor.